argenx SE (ARGX)
981.33
+3.75
(+0.38%)
USD |
NASDAQ |
Nov 12, 16:00
980.52
-0.81
(-0.08%)
After-Hours: 20:00
argenx Enterprise Value : 60.66B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 60.66B |
| November 11, 2026 | 60.43B |
| November 10, 2026 | 60.05B |
| November 09, 2026 | 59.48B |
| November 06, 2026 | 57.31B |
| November 05, 2026 | 55.30B |
| November 04, 2026 | 57.57B |
| November 03, 2026 | 55.70B |
| November 02, 2026 | 54.08B |
| October 30, 2026 | 55.19B |
| October 29, 2026 | 55.49B |
| October 28, 2026 | 55.12B |
| October 27, 2026 | 54.54B |
| October 26, 2026 | 53.73B |
| October 23, 2026 | 54.00B |
| October 22, 2026 | 54.13B |
| October 21, 2026 | 55.01B |
| October 20, 2026 | 53.75B |
| October 19, 2026 | 51.02B |
| October 16, 2026 | 50.62B |
| October 15, 2026 | 52.30B |
| October 14, 2026 | 50.57B |
| October 13, 2026 | 49.60B |
| October 12, 2026 | 50.20B |
| October 09, 2026 | 50.99B |
| Date | Value |
|---|---|
| October 08, 2026 | 50.59B |
| October 07, 2026 | 57.39B |
| October 06, 2026 | 57.52B |
| October 05, 2026 | 56.42B |
| October 02, 2026 | 56.82B |
| October 01, 2026 | 57.86B |
| September 30, 2026 | 59.27B |
| September 29, 2026 | 60.00B |
| September 28, 2026 | 60.10B |
| September 25, 2026 | 59.31B |
| September 24, 2026 | 59.48B |
| September 23, 2026 | 58.46B |
| September 22, 2026 | 59.57B |
| September 21, 2026 | 61.09B |
| September 18, 2026 | 61.22B |
| September 17, 2026 | 61.55B |
| September 16, 2026 | 60.87B |
| September 15, 2026 | 60.56B |
| September 14, 2026 | 61.23B |
| September 11, 2026 | 60.85B |
| September 10, 2026 | 60.83B |
| September 09, 2026 | 61.96B |
| September 08, 2026 | 62.25B |
| September 04, 2026 | 63.87B |
| September 03, 2026 | 65.12B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Autolus Therapeutics Plc | 508.24M |
| Cellectis SA | 71.36M |
| Halozyme Therapeutics, Inc. | 13.65B |
| DBV Technologies SA | 574.77M |
| Akari Therapeutics Plc | 4.334M |
Enterprise Value Related Metrics
| Earnings Yield | 2.67% |
| Operating Earnings Yield | 2.35% |
| Normalized Earnings Yield | 2.674 |